Search
TAFA-93
go.drugbank.com/drugs/DB05887Experimentalclinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalDeramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders.
Glypromate
go.drugbank.com/drugs/DB05633ExperimentalNeuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.
RUTI® Vaccine
go.drugbank.com/drugs/DB15853InvestigationalMuch like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … Sponsored by Fundació Institut Germans Trias i Pujol, the RUTI® Vaccine is being tested for prevention of COVID-19 infection in a controlled trial with 315 healthcare worker participants (NCT04453488).
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIn June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalPPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that ...
LJP 1082
go.drugbank.com/drugs/DB05446ExperimentalLJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis.
VIT-100
go.drugbank.com/drugs/DB05865ExperimentalVIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a ...
BOS172722
go.drugbank.com/drugs/DB15498InvestigationalThe key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]